vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Local Bounti Corporation (LOCL). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $12.5M, roughly 1.3× Local Bounti Corporation). Journey Medical Corp runs the higher net margin — -7.8% vs -69.8%, a 62.1% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 23.7%). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.
DERM vs LOCL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $12.5M |
| Net Profit | $-1.2M | $-8.7M |
| Gross Margin | — | 12.2% |
| Operating Margin | -2.8% | -106.1% |
| Net Margin | -7.8% | -69.8% |
| Revenue YoY | 27.3% | 23.7% |
| Net Profit YoY | -182.0% | 76.0% |
| EPS (diluted) | $-0.04 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $12.5M | ||
| Q3 25 | $17.0M | $12.2M | ||
| Q2 25 | $15.0M | $12.1M | ||
| Q1 25 | $13.1M | $11.6M | ||
| Q4 24 | $12.6M | $10.1M | ||
| Q3 24 | $14.6M | $10.2M | ||
| Q2 24 | $14.9M | $9.4M | ||
| Q1 24 | $13.0M | $8.4M |
| Q4 25 | $-1.2M | $-8.7M | ||
| Q3 25 | $-2.3M | $-26.4M | ||
| Q2 25 | $-3.8M | $-21.6M | ||
| Q1 25 | $-4.1M | $-37.7M | ||
| Q4 24 | $1.5M | $-36.3M | ||
| Q3 24 | $-2.4M | $-34.3M | ||
| Q2 24 | $-3.4M | $-25.3M | ||
| Q1 24 | $-10.4M | $-24.1M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 12.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | 82.3% | 5.4% | ||
| Q3 24 | 63.9% | 13.8% | ||
| Q2 24 | 56.0% | 14.3% | ||
| Q1 24 | 47.7% | 9.4% |
| Q4 25 | -2.8% | -106.1% | ||
| Q3 25 | -9.0% | -149.4% | ||
| Q2 25 | -19.2% | -127.7% | ||
| Q1 25 | -25.3% | -135.6% | ||
| Q4 24 | 17.7% | -166.6% | ||
| Q3 24 | -19.8% | -176.0% | ||
| Q2 24 | -19.7% | -146.8% | ||
| Q1 24 | -77.4% | -122.9% |
| Q4 25 | -7.8% | -69.8% | ||
| Q3 25 | -13.6% | -216.6% | ||
| Q2 25 | -25.3% | -178.3% | ||
| Q1 25 | -31.0% | -324.6% | ||
| Q4 24 | 12.1% | -360.1% | ||
| Q3 24 | -16.3% | -335.2% | ||
| Q2 24 | -22.6% | -267.6% | ||
| Q1 24 | -80.1% | -286.9% |
| Q4 25 | $-0.04 | $1.52 | ||
| Q3 25 | $-0.09 | $-1.18 | ||
| Q2 25 | $-0.16 | $-1.63 | ||
| Q1 25 | $-0.18 | $-4.32 | ||
| Q4 24 | $0.10 | $-4.24 | ||
| Q3 24 | $-0.12 | $-4.01 | ||
| Q2 24 | $-0.17 | $-3.00 | ||
| Q1 24 | $-0.53 | $-2.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $4.2M |
| Total DebtLower is stronger | $25.3M | $483.1M |
| Stockholders' EquityBook value | $31.9M | $-166.2M |
| Total Assets | $94.6M | $410.5M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $4.2M | ||
| Q3 25 | $24.9M | $6.2M | ||
| Q2 25 | $20.3M | $5.3M | ||
| Q1 25 | $21.1M | $18.0M | ||
| Q4 24 | $20.3M | $937.0K | ||
| Q3 24 | $22.5M | $317.0K | ||
| Q2 24 | $23.9M | $9.7M | ||
| Q1 24 | $24.1M | $8.2M |
| Q4 25 | $25.3M | $483.1M | ||
| Q3 25 | $25.2M | $484.9M | ||
| Q2 25 | $25.1M | $478.3M | ||
| Q1 25 | $25.0M | $480.0M | ||
| Q4 24 | $24.9M | $436.8M | ||
| Q3 24 | $19.8M | $398.4M | ||
| Q2 24 | $19.7M | $374.0M | ||
| Q1 24 | $14.7M | $329.8M |
| Q4 25 | $31.9M | $-166.2M | ||
| Q3 25 | $25.9M | $-158.1M | ||
| Q2 25 | $19.2M | $-132.7M | ||
| Q1 25 | $21.5M | $-134.5M | ||
| Q4 24 | $20.1M | $-100.5M | ||
| Q3 24 | $10.9M | $-65.6M | ||
| Q2 24 | $11.3M | $-32.8M | ||
| Q1 24 | $13.0M | $-9.4M |
| Q4 25 | $94.6M | $410.5M | ||
| Q3 25 | $85.2M | $417.8M | ||
| Q2 25 | $81.2M | $426.8M | ||
| Q1 25 | $85.0M | $447.2M | ||
| Q4 24 | $80.2M | $428.0M | ||
| Q3 24 | $64.0M | $430.8M | ||
| Q2 24 | $65.2M | $438.1M | ||
| Q1 24 | $66.6M | $413.4M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-3.1M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -29.1% |
| Capex IntensityCapex / Revenue | — | 3.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-42.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-3.1M | ||
| Q3 25 | $-2.4M | $-8.9M | ||
| Q2 25 | $-942.0K | $-8.7M | ||
| Q1 25 | $-2.8M | $-9.6M | ||
| Q4 24 | $2.2M | $1.2M | ||
| Q3 24 | $-1.2M | $-17.2M | ||
| Q2 24 | $-5.2M | $-4.0M | ||
| Q1 24 | $-5.0M | $-7.1M |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-10.1M | ||
| Q2 25 | — | $-14.6M | ||
| Q1 25 | — | $-14.5M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | — | $-30.0M | ||
| Q2 24 | — | $-28.8M | ||
| Q1 24 | — | $-42.1M |
| Q4 25 | — | -29.1% | ||
| Q3 25 | — | -82.8% | ||
| Q2 25 | — | -121.0% | ||
| Q1 25 | — | -125.1% | ||
| Q4 24 | — | -85.3% | ||
| Q3 24 | — | -293.1% | ||
| Q2 24 | — | -305.4% | ||
| Q1 24 | — | -501.8% |
| Q4 25 | — | 3.9% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | — | 48.9% | ||
| Q1 25 | — | 42.8% | ||
| Q4 24 | — | 97.6% | ||
| Q3 24 | — | 125.0% | ||
| Q2 24 | — | 263.0% | ||
| Q1 24 | — | 417.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
LOCL
Segment breakdown not available.
